FSFrancesco Serra

Francesco Serra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesco Serra has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Paolo Pedrazzoli

    Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy

    5 shared publications
  • Riccardo Caccialanza

    Clinical Nutrition and Dietetics Unit, Department of Oncology, Comprehensive Cancer Center, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy

    4 shared publications
  • Anna Pagani

    Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy

    3 shared publications
  • Jacopo Viganò

    Department of General Surgery, Hospital Policlinico San Matteo of Pavia, Pavia, Italy

    3 shared publications
  • Salvatore Corallo

    Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy

    3 shared publications
  • Anna Gallotti

    Department of Radiology, Hospital Policlinico San Matteo of Pavia, Pavia, Italy

    2 shared publications

Latest Publications

  • Open Access

    Multimodal treatment of pineal metastasis from oesophageal adenocarcinoma

    by Francesca Rifaldi, Domiziana Alaimo, Anna Tortorella, Ilaria Imarisio, Anna Pagani, Salvatore Corallo, Paolo Pedrazzoli, Daniela Cicognini, Viola Custodi, Francesco Guerrini, et al.

    The authors present a case of pineal metastasis from oesophageal adenocarcinoma managed by multimodal treatment and compare their observations with the available literature on this disease entity.


  • Open Access

    Real-life effectiveness of FLOT in resectable gastric cancer: existing challenges

    by Francesco Serra, Federica Valerio, Paolo Pedrazzoli, Jacopo Viganò, Riccardo Caccialanza, Daniela Cicognini, Anna Pagani, Salvatore Corallo

    This article aims to demonstrate the real-life effectiveness of the fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) regimen by comparing it with traditional chemotherapy regimens and aims to discover its strengths and weaknesses.


  • What are we doing concretely for the food prevention of cancer? Nutrition between scientific evidence and myopic policies

    by Francesco Serra, Riccardo Caccialanza, Paolo Pedrazzoli

    In this Commentary, the role of diet in cancer is discussed following the scientific evidence suggesting that excessive consumption of red meat and processed foods is correlated with a greater risk of contracting cancer.

  • Open Access

    Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies

    by Roberto Aquilani, Silvia Brugnatelli, Roberto Maestri, Paolo Iadarola, Salvatore Corallo, Anna Pagani, Francesco Serra, Anna Bellini, Daniela Buonocore, Maurizia Dossena, et al.

    Previous studies have documented that FOLFOX and XELOX therapies negatively impact the metabolism of skeletal muscle and extra-muscle districts. This pilot study tested whether three-month FOLFOX or XELOX therapy produced changes in plasma amino acid levels (PAAL) (an estimation of whole-body amino acid metabolism) and in plasma levels of malondialdehyde (MDA), a marker of lipid hyper oxidation. Fourteen ambulatory, resected patients with colorectal cancer scheduled to receive FOLFOX (n = 9) or XELOX (n = 5) therapy, after overnight fasting, underwent peripheral venous blood sampling, to determine PAAL and MDA before, during, and at the end of three-month therapy. Fifteen healthy matched subjects (controls) only underwent measures of PAAL at baseline. The results showed changes in 87.5% of plasma essential amino acids (EAAs) and 38.4% of non-EAAs in patients treated with FOLFOX or XELOX. These changes in EAAs occurred in two opposite directions: EAAs decreased with FOLFOX and increased or did not decrease with XELOX (interactions: from p = 0.034 to p = 0.003). Baseline plasma MDA levels in both FOLFOX and XELOX patients were above the normal range of values, and increased, albeit not significantly, during therapy. In conclusion, three-month FOLFOX or XELOX therapy affected plasma EAAs differently but not the baseline MDA levels, which were already high.


  • Open Access

    The Key Role of Patient Empowerment in the Future Management of Cancer-Related Malnutrition

    by Amanda Casirati, Valentina Da Prat, Emanuele Cereda, Francesco Serra, Lorenzo Perrone, Salvatore Corallo, Francesco De Lorenzo, Paolo Pedrazzoli, Riccardo Caccialanza

    Malnutrition is a common condition in cancer patients


  • Open Access

    Nutritional support management in resectable gastric cancer

    by Francesco Serra, Paolo Pedrazzoli, Silvia Brugnatelli, Anna Pagani, Salvatore Corallo, Giovanni Rosti, Riccardo Caccialanza, Jacopo Viganò, Ornella Carminati

    This narrative review presents the most recent data on nutritional support in the resectable stages of gastric cancer, with a particular focus on perioperative strategies, and discusses malnutrition in gastric cancer, nutritional support before and after surgery, and the relationship between nutritional support and chemotherapy.


  • Open Access

    Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

    by Francesco Serra, Carlotta Faverio, Angioletta Lasagna, Stefania Barruscotti, Tommaso Dominioni, Marco Benazzo, Paolo Pedrazzoli, Silvia Chiellino

    The clinical management of BRAF-mutated metastatic melanoma had an important turning point after the introduction of the targeted therapy. Despite the efficacy and good tolerability of this treatment, the development of resistance mechanisms causes disease progression. The aim of this review is to investigate the role of treatment beyond progression and locoregional approaches in BRAF-mutated metastatic melanoma and provide oncologists dealing with this malignancy a useful road map on when and why to choose this strategy.


  • Open Access

    Pancreatic nodule positive for 68-Ga-DOTAPEPTIDE-PET: NET or ectopic spleen? The importance of a good differential diagnosis

    by Francesco Serra, Gianluca De Matteis, Sara Delfanti, Monica Feltri, Alessandro Vanoli, Giorgio Cavenaghi, Anna Gallotti, Marcello Maestri, Silvia Brugnatelli

    Background: Accessory spleen is a congenital defect in which splenic tissue is present outside the spleen. In 20% of cases, accessory spleen is localized within the pancreatic tail, a condition known as IPAS. The identification of this benign anomaly, which affects about 2% of general population, is not easy because it is often mistaken for a pNET which is more common, at around 5%. A 68-Ga-DOTAPEPTIDE-PET normally identifies pNETs with high rate of sensitivity and specificity, but in some conditions, it produces false positives, including IPAS. Materials and tools: A clinical case we recently encountered, prompted us to review the available medical literature on the topic. Typing “intrapancreatic accessory spleen” into PubMed database and limiting research to the last 10 years yielded 121 results from which we selected the most relevant articles for decision-making, with a brief explanation of the reasons for selecting those. Our analysis focused on the most critical and least descriptive articles, those which clearly indicated the importance of differential diagnosis by promoting the use of advanced investigations in case of pancreatic nodule suspected for IPAS. Ultimately, our objective was to update the available guidelines recommendations. Discussion and conclusions: Despite concern in the medical literature, a differential IPAS diagnosis is still subordinate to other clinical, radiological, nuclear medicine, and cytological criteria. After reviewing the literature, we recommend that IPAS should always be considered as a possibility before diagnosis of pNET is made. IPAS should be suspected in the presence of the following findings: asymptomatic pancreatic nodule found incidentally, absence of laboratory findings of NETs, localization in the pancreatic tail, between 1 and 3 cm in size with well-defined margins, homogeneous enhancement, and similar attenuation to the spleen on CT and MRI. In these cases, the use of advanced investigations beyond 68-Ga-DOTAPEPTIDE-PET must be systematic. The recognition of IPAS is not only a diagnostic refinement, but it also avoids unnecessary surgery for the patient.